Search results
Showing 631 to 645 of 1214 results for pain
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.
Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.
This evidence summary has been updated and replaced by NICE guideline NG193.
Irreversible electroporation for treating prostate cancer (HTG688)
Evidence-based recommendations on irreversible electroporation for treating prostate cancer. This involves using electrical pulses to destroy the cancer cells.
View recommendations for HTG688Show all sections
Irreversible electroporation for treating renal cancer (HTG303)
Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.
View recommendations for HTG303Show all sections
Sections for HTG303
High-intensity focused ultrasound for prostate cancer (HTG70)
Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer. This involves inserting a probe through the rectum that gives out a beam of ultrasound to heat and destroy the cancerous prostate tissue.
View recommendations for HTG70Show all sections
Sections for HTG70
Evidence-based recommendations on ab interno canaloplasty for open-angle glaucoma. This involves widening the channel that drains fluid from the eye. The aim is to reduce pressure in the eye.
View recommendations for HTG647Show all sections
Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease (HTG318)
Evidence-based recommendations on endoscopic radiofrequency ablation for gastro-oesophageal reflux disease. This involves using heat from electrodes to change the tissues in the oesophagus, with the aim of reducing symptoms.
Wireless capsule endoscopy for investigation of the small bowel (HTG62)
Evidence-based recommendations on wireless capsule endoscopy for investigation of the small bowel. This involves the person swallowing a small capsule containing a tiny camera that takes pictures as it passes through the body.
View recommendations for HTG62Show all sections
Sections for HTG62
Percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access (HTG597)
Evidence-based recommendations on percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access in adults. This involves using radiofrequency energy, or heat and pressure, to join an artery and vein in the forearm to create a fistula for haemodialysis access.
View recommendations for HTG597Show all sections
Cryotherapy as a primary treatment for prostate cancer (HTG91)
Evidence-based recommendations on cryotherapy as a primary treatment for prostate cancer. This involves using cold temperature to freeze and destroy cancer tissue as a first treatment for cancer that hasn't spread far from the prostate.
View recommendations for HTG91Show all sections
Sections for HTG91
important:- Endometriosis is a long-term condition that can cause acute and chronic pain, and fatigue. It has a significant and...
Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)
Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making
This guideline covers systems and processes for using and managing controlled drugs safely in all NHS settings except care homes. It aims to improve working practices to comply with legislation and have robust governance arrangements. It also aims to reduce the safety risks associated with controlled drugs.
Urinary tract infection in under 16s: diagnosis and management (NG224)
This guideline covers diagnosing and managing first or recurrent upper or lower urinary tract infection (UTI) in babies, children and young people under 16. It aims to achieve more consistent clinical practice, based on accurate diagnosis and effective management. It does not cover babies, children and young people with urinary catheters in situ, neurogenic bladders, significant pre-existing urinary tract disorders (uropathies), underlying renal disease or immunosuppression, or recurrent UTI in sexually active girls and young women under 16. It also does not cover babies, children and young people in intensive care units.